WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205990
Description: Radotinib, also known as IY-5511, is an orally available, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways.
MedKoo Cat#: 205990
Chemical Formula: C27H21F3N8O
Exact Mass: 530.17904
Molecular Weight: 530.5
Elemental Analysis: C, 61.13; H, 3.99; F, 10.74; N, 21.12; O, 3.02
Synonym: IY5511; IY-5511; IY 5511; IY5511 HCl; Radotinib; trade name Supect.
IUPAC/Chemical Name: 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzamide
InChi Key: DUPWHXBITIZIKZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
SMILES Code: O=C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=NC=CN=C5)=N4)=C3
Radotinib (INN; trade name Supect) is a drug for the treatment of some types of cancer. It is approved in Korea for use as a second-line treatment of chronic myeloid leukemia (CML). Its mechanism of action involves inhibition of the tyrosine kinase Bcr-Abl and of platelet-derived growth factor receptor (PDGFR). (http://en.wikipedia.org/wiki/Radotinib).
The chemical structure of radotinib is very similar to imatinib. (see the following graphic)
Side by side comparison of chemical structures between radotinib and imatinib
1: Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Apr 4. [Epub ahead of print] PubMed PMID: 24705186.